luminol has been researched along with Brain Disorders in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ge, J; Gordon, A; Li, B; Li, P; Sun, R; Yang, H; Zhang, Y | 1 |
| Ercan, F; Gedik, N; Keyer-Uysal, M; Sener, G; Toklu, HZ; Tunali Akbay, T; Velioglu-Ogunc, A | 1 |
2 other study(ies) available for luminol and Brain Disorders
| Article | Year |
|---|---|
3-Aminophthalhydrazide (Luminol) As a Matrix for Dual-Polarity MALDI MS Imaging.
Topics: Animals; Brain; Brain Diseases; Brain Ischemia; Infarction, Middle Cerebral Artery; Luminescent Agents; Luminol; Mice; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2019 |
Silymarin, the antioxidant component of Silybum marianum, prevents sepsis-induced acute lung and brain injury.
Topics: Acridines; Animals; Anti-Inflammatory Agents; Antioxidants; Brain; Brain Diseases; Female; Glutathione; L-Lactate Dehydrogenase; Luminescent Agents; Luminol; Male; Peroxidase; Pulmonary Alveoli; Rats; Rats, Wistar; Respiratory Distress Syndrome; Sepsis; Silybum marianum; Silymarin; Survival Rate; Thromboplastin; Tumor Necrosis Factor-alpha | 2008 |